[
  {
    "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
    "bbox": [
      156,
      83,
      1000,
      95
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
    "bbox": [
      110,
      98,
      891,
      111
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
    "bbox": [
      155,
      129,
      1000,
      142
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
    "bbox": [
      110,
      145,
      1000,
      158
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
    "bbox": [
      156,
      176,
      1000,
      188
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
    "bbox": [
      111,
      192,
      1000,
      204
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
    "bbox": [
      155,
      222,
      1000,
      235
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
    "bbox": [
      110,
      239,
      1000,
      251
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
    "bbox": [
      110,
      253,
      1000,
      266
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
    "bbox": [
      111,
      269,
      1000,
      282
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
    "bbox": [
      113,
      286,
      1000,
      296
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
    "bbox": [
      111,
      300,
      1000,
      313
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
    "bbox": [
      111,
      316,
      1000,
      328
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
    "bbox": [
      111,
      332,
      1000,
      343
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
    "bbox": [
      111,
      348,
      1000,
      358
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
    "bbox": [
      111,
      363,
      1000,
      375
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
    "bbox": [
      111,
      378,
      1000,
      390
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
    "bbox": [
      111,
      393,
      1000,
      405
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
    "bbox": [
      111,
      408,
      1000,
      421
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
    "bbox": [
      155,
      440,
      1000,
      453
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
    "bbox": [
      113,
      456,
      1000,
      468
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
    "bbox": [
      156,
      485,
      1000,
      499
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
    "bbox": [
      111,
      502,
      1000,
      514
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
    "bbox": [
      110,
      518,
      1000,
      530
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "2",
    "bbox": [
      664,
      533,
      677,
      543
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
    "bbox": [
      156,
      83,
      1000,
      95
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
    "bbox": [
      110,
      98,
      891,
      111
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
    "bbox": [
      155,
      129,
      1000,
      142
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
    "bbox": [
      110,
      145,
      1000,
      158
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
    "bbox": [
      156,
      176,
      1000,
      188
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
    "bbox": [
      111,
      192,
      1000,
      204
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
    "bbox": [
      155,
      222,
      1000,
      235
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
    "bbox": [
      110,
      239,
      1000,
      251
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
    "bbox": [
      110,
      253,
      1000,
      266
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
    "bbox": [
      111,
      269,
      1000,
      282
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
    "bbox": [
      113,
      286,
      1000,
      296
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
    "bbox": [
      111,
      300,
      1000,
      313
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
    "bbox": [
      111,
      316,
      1000,
      328
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
    "bbox": [
      111,
      332,
      1000,
      343
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
    "bbox": [
      111,
      348,
      1000,
      358
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
    "bbox": [
      111,
      363,
      1000,
      375
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
    "bbox": [
      111,
      378,
      1000,
      390
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
    "bbox": [
      111,
      393,
      1000,
      405
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
    "bbox": [
      111,
      408,
      1000,
      421
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
    "bbox": [
      155,
      440,
      1000,
      453
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
    "bbox": [
      113,
      456,
      1000,
      468
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
    "bbox": [
      156,
      485,
      1000,
      499
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
    "bbox": [
      111,
      502,
      1000,
      514
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
    "bbox": [
      110,
      518,
      1000,
      530
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "2",
    "bbox": [
      664,
      533,
      677,
      543
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
    "bbox": [
      156,
      83,
      1000,
      95
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
    "bbox": [
      110,
      98,
      891,
      111
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
    "bbox": [
      155,
      129,
      1000,
      142
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
    "bbox": [
      110,
      145,
      1000,
      158
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
    "bbox": [
      156,
      176,
      1000,
      188
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
    "bbox": [
      111,
      192,
      1000,
      204
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
    "bbox": [
      155,
      222,
      1000,
      235
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
    "bbox": [
      110,
      239,
      1000,
      251
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
    "bbox": [
      110,
      253,
      1000,
      266
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
    "bbox": [
      111,
      269,
      1000,
      282
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
    "bbox": [
      113,
      286,
      1000,
      296
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
    "bbox": [
      111,
      300,
      1000,
      313
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
    "bbox": [
      111,
      316,
      1000,
      328
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
    "bbox": [
      111,
      332,
      1000,
      343
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
    "bbox": [
      111,
      348,
      1000,
      358
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
    "bbox": [
      111,
      363,
      1000,
      375
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
    "bbox": [
      111,
      378,
      1000,
      390
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
    "bbox": [
      111,
      393,
      1000,
      405
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
    "bbox": [
      111,
      408,
      1000,
      421
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
    "bbox": [
      155,
      440,
      1000,
      453
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
    "bbox": [
      113,
      456,
      1000,
      468
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
    "bbox": [
      156,
      485,
      1000,
      499
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
    "bbox": [
      111,
      502,
      1000,
      514
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
    "bbox": [
      110,
      518,
      1000,
      530
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "2",
    "bbox": [
      664,
      533,
      677,
      543
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  }
]